Complications; Cesarean Section Clinical Trial
Official title:
Intravenous Oxytocin Use to Decrease Blood Loss During Cesarean Section. What is the Optimal Dose: A Randomized Blinded Trial
The goal of this study is to determine the best dose of a drug called oxytocin, that is usually used to stop bleeding during a delivery, when used during a cesarean delivery. It will be administered during cesarean section in order to decrease the amount blood loss. The investigators are proposing to have 3 groups of subjects each given a different safe dose of oxytocin and then to assess the effectiveness of each regimens on the amount blood lost during cesarean sections.This will let use know which is the best lowest dose needed.
This trial will be a randomized, blinded controlled trial that will be conducted at the
American University of Beirut Medical Center Labor and Delivery Unit.
Identification of candidates:
- All women admitted to the Delivery Suite for elective cesarean delivery or needing
cesarean delivery for obstetric reasons will be invited to participate in the study.
- Women will then be approached by the research assistants and/or investigators who will
explain the objectives of the study and will ask eligible women to participate in the
trial and sign a consent form.
Study subjects will be randomized using a computer-generated random number sequence
stratified by elective or emergency cesarean section. At surgery, a sealed opaque envelope
containing the randomization number and data sheet will be opened for each consenting
patient.
Interventions:
Pre-mixed, oxytocin solutions with either 20U/500ml, 30U/500ml or 40U/500ml of Lactated
Ringer's solution will be available in the pharmacy department. The bags will be identical
in appearance. Each bag will be labeled with a study identification number, from which the
pharmacy could determine the administered dose. Subjects as well as the medical providers
will be blinded to the assignment of the solution used.
Immediately after delivery of the infant, the study solution will be infused over 30 minutes
using a continuous infusion pump (666 mU/min versus 999 mU/min versus 1332mU/min). The
placenta will be delivered spontaneously with gentle cord traction. In the postanesthesia
care unit, our practice is to give all patients a mixture of 30 U, 20 U and 10U of oxytocin
to run consecutively in 1 L of lactated Ringer's solution at a rate of 125 mL/h (41.7
mU/min), which will be continued for a total of 24 hours.
Determination of the need for additional uterotonic agents will be made by the obstetrician
and administered and recorded by the anesthesiologist. At the discretion of the surgical
team, additional oxytocin could be added to the study solution (eg, 20 U) before requesting
methylergonovine, 0.2 mg IM, or 15-methyl prostaglandin F2a 250 mg IM. Intramuscular
methylergonovine maleate, and/or carboprost tromethamine will be available in the operating
room and will be administered if needed. Ephedrine will be used to treat hypotension after
delivery if the systolic blood pressure is >25 mm Hg below baseline.
We will be comparing the mean difference of preoperative hemoglobin vs. postoperative
hemoglobin in each group. It will be referred to as delta Hemoglobin (Δ Hb).
In addition, we will be assessing several parameters including uterine tone, volume of blood
lost and laparotomy pads number and weight among other data.
We will be performing multiple comparisons among the 3 groups specifically towards our
primary outcome which is change or drop in hemoglobin from predelivery to postdelivery
level.
The arm of the study with the lowest dose of pitocin and with the least amount of blood loss
would probably be the optimal dose needed during a cesarean section for a patient that
satisfies all the inclusion criteria of this trial.
In most institutions worldwide, a protocol is usually applied that states how much pitocin
should be added to a 1 liter bag of NS or LR during cesarean section. It often ranges from
10 units to 40 units depending on the surgeons preference and uterine tone. The uterus is
exteriorized most of the time during the surgery. The uterine tone does play a role in the
choice of which dose id to be used(low versus high dose), however the optimal, most
efficient dose with the least amount of side effects is yet to be determined. We are aiming
to determine the optimal dose that will prevent the obstetricians from the additional use of
other uterotonics (methergine, prostaglandins) that carries of by themselves unwanted side
effects.
;
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Prevention
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03052699 -
Medium and Long-term Complications of the Patients Having Had a Vaginal Caesarian in Hospital René Dubos
|
N/A | |
Completed |
NCT01412073 -
Control of Blood Loss During Caesarean Section
|
Phase 3 | |
Completed |
NCT01851187 -
Effect of Perinatal Emotional Management on Maternal Emotion and Delivery Outcomes
|
N/A | |
Completed |
NCT01890720 -
Incisional Negative Pressure Wound Therapy for Prevention of Postoperative Infections Following Caesarean Section
|
N/A | |
Completed |
NCT02542748 -
Comparison of Norepinephrine and Ephedrine on Hypotension After Spinal Anesthesia in Parturients
|
N/A | |
Enrolling by invitation |
NCT02694653 -
Preoperative Cesarean Section Intravenous Acetaminophen and Postoperative Pain Control
|
Phase 1 | |
Completed |
NCT01723605 -
Insitu Repair Versus Uterine Exeriorization During Cesarean Section
|
Phase 3 | |
Withdrawn |
NCT01516697 -
Non-invasive Cardiac Output Monitoring in Obstetric Patients
|
Phase 4 | |
Completed |
NCT01741610 -
Fluid Coloading and the Incidence of Hypotension
|
Phase 4 | |
Terminated |
NCT02838017 -
Tissue Adhesive vs. Sterile Strips After Cesarean Delivery
|
N/A | |
Completed |
NCT02587013 -
Comparison of Uterine Repair Methods for Cesarean Delivery
|
N/A | |
Terminated |
NCT02036697 -
Hemodynamic Effects of Low Dose Spinal Anesthesia for Cesarean Section
|
N/A | |
Recruiting |
NCT01954719 -
Is Routine Cervical Dilatation Necessary During Elective Caesarean Section? A Randomised Controlled Trial
|
N/A | |
Terminated |
NCT02799667 -
Do Single Use Negative Pressure Dressings Reduce Wound Complications in Obese Women After Cesarean Delivery
|
N/A | |
Completed |
NCT02459093 -
Subcuticular Suture for Cesarean Skin Incision Closure
|
Phase 4 | |
Completed |
NCT01858467 -
Supreme LMA and Endotracheal Intubation Use in Caesarean Section
|
N/A | |
Completed |
NCT01891006 -
Intervention for Postpartum Infections Following Caesarean Section
|
N/A | |
Withdrawn |
NCT02893696 -
Extra Sitting Time After Spinal Anesthesia for Cesarean Section and Fetal Well-being
|
N/A | |
Completed |
NCT02785094 -
Education and Social Media Versus Non-Indicated Caesarean Section Rate in Egypt
|
N/A | |
Completed |
NCT02332278 -
Early Oral Feeding Versus Traditional Postoperative Care After Cesarean Section.
|
N/A |